Imatinib - Pharm-SintezAlternative Names: Imatib
Latest Information Update: 31 Oct 2015
At a glance
- Originator Pharm-Sintez
- Class Antineoplastics; Antivirals; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Hypereosinophilic syndrome; Myelodysplastic syndromes; Myeloproliferative disorders; Systemic mastocytosis
Most Recent Events
- 15 Mar 2016 Biomarkers information updated